Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis by Bah, Germanus S et al.
RESEARCH ARTICLE
Emodepside targets SLO-1 channels of
Onchocerca ochengi and induces broad




2, Steffen R. Hahnel3¤, Nicolas
H. BayangID
1, Helena FieselerID
3, Gabriele M. Schmuck3, Ralph Krebber4, Anouk Sarr5,
Carsten TerjungID
6, Henrietta F. NgangyungID
1, David D. Ekale1, Youssouf M. Mfopit1,
Lucien RufenerID
5, John Graham-BrownID
7, Vincent N. TanyaID
1,8, Martin Glenschek-
SieberthID
9, Daniel Kulke3¤, Benjamin L. MakepeaceID
7*
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Abstract
Onchocerciasis (river blindness), caused by the filarial worm Onchocerca volvulus, is a
neglected tropical disease mostly affecting sub-Saharan Africa and is responsible for >1.3
million years lived with disability. Current control relies almost entirely on ivermectin, which
suppresses symptoms caused by the first-stage larvae (microfilariae) but does not kill the
long-lived adults. Here, we evaluated emodepside, a semi-synthetic cyclooctadepsipeptide
registered for deworming applications in companion animals, for activity against adult filariae
(i.e., as a macrofilaricide). We demonstrate the equivalence of emodepside activity on SLO-
1 potassium channels in Onchocerca volvulus and Onchocerca ochengi, its sister species
from cattle. Evaluation of emodepside in cattle as single or 7-day treatments at two doses
(0.15 and 0.75 mg/kg) revealed rapid activity against microfilariae, prolonged suppression
of female worm fecundity, and macrofilaricidal effects by 18 months post treatment. The
drug was well tolerated, causing only transiently increased blood glucose. Female adult
worms were mostly paralyzed; however, some retained metabolic activity even in the multi-
ple high-dose group. These data support ongoing clinical development of emodepside to
treat river blindness.







Citation: Bah GS, Schneckener S, Hahnel SR,
Bayang NH, Fieseler H, Schmuck GM, et al. (2021)
Emodepside targets SLO-1 channels of
Onchocerca ochengi and induces broad
anthelmintic effects in a bovine model of
onchocerciasis. PLoS Pathog 17(6): e1009601.
https://doi.org/10.1371/journal.ppat.1009601
Editor: Makedonka Mitreva, Washington University
School of Medicine, UNITED STATES
Received: January 5, 2021
Accepted: May 1, 2021
Published: June 2, 2021
Copyright: © 2021 Bah et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: All raw data
underpinning this study are publicly available at
Dryad (https://datadryad.org/stash) with the
identifier doi:10.5061/dryad.vhhmgqns0.
Funding: This study was funded by Bayer AG
(https://www.bayer.com/en) through contract
research awarded to BLM (University of Liverpool)
and to AS and LR (INVENesis). SS, HF, SRH, GMS,
RK, CT, MGS, and DK are employees of Bayer, or
were employees of Bayer when the work was
Author summary
Onchocerciasis (river blindness), caused by the parasitic worm Onchocerca volvulus, is a
devastating neglected tropical disease affecting sub-Saharan Africa with an overall impact
of>1.3 million years lived with disability. Current control relies mainly on a single drug,
ivermectin, which suppresses symptoms caused by the first-stage larvae (microfilariae)
but does not kill the long-lived adults. The identification of a drug that can safely eliminate
adult worms (i.e., a macrofilaricide) is a major research objective for onchocerciasis. We
evaluated the anthelminthic activity of emodepside, a veterinary wormer, in cattle infected
with a close relative of O. volvulus (Onchocerca ochengi) before conducting pharmacoki-
netic modelling to estimate drug distribution in humans. Emodepside as single or 7-day
treatments at two doses produced rapid activity against O. ochengimicrofilariae, pro-
longed suppression of female worm fecundity, and paralysed most female worms by 18
months, although some remained metabolically active even in the multiple high-dose
treatment group. The drug was well tolerated, causing only transiently increased blood
glucose. Thus, emodepside shows slow but significant efficacy against adult O. ochengi in
naturally infected cattle, meeting the criteria for a safe macrofilaricidal drug. Our data
support the ongoing clinical development of emodepside for the treatment of human
onchocerciasis.
Introduction
Onchocerciasis is a neglected tropical disease caused by a parasitic worm, Onchocerca volvulus,
which belongs to the vector-transmitted superfamily Filarioidea (the filarial nematodes). The
vector that carries the parasite (blackfly Simulium spp.) requires fast-flowing water during its
larval stage, and infection with the parasite affects the skin and eyes, causing severe dermatitis
and keratitis; hence the disease is colloquially known as river blindness. Onchocerciasis has
been the subject of one of the longest-running series of control programmes in the history of
tropical medicine, spanning 45 years [1], yet 21 million people remain infected and the current
disease burden has been estimated as>1.3 million years lived with disability [2]. The disease is
heavily concentrated in sub-Saharan Africa, though hotspots remain in Yemen and Amazonia.
Onchocerciasis control originally focused on the vector, but since the late 1980s this
approach has been largely superseded by mass drug administration (MDA) with a single com-
pound, ivermectin (IVM; trade name “Mectizan”) which targets the worm [3]. In most
endemic foci in sub-Saharan Africa, IVM is distributed once annually, killing the first-stage
larvae (microfilariae, Mf) in the skin and thus preventing disease manifestations. This regimen
also suppresses the release of new Mf from the adult female worm for several months [4]. In
foci with seasonal transmission, MDA with IVM (which may include semi-annual treatments)
has also been demonstrated to be capable of breaking transmission, typically after an interval
of 15–25 years [5,6]. The long period of MDA required to abrogate transmission is due to the
longevity of the adult worms [7], as the female can be reproductively active for more than 10
years and is only temporarily sterilised, not destroyed, by IVM treatments. Although the cur-
rent World Health Organization (WHO) strategy is to eliminate onchocerciasis by MDA,
modelling suggests that IVM alone cannot achieve elimination until the 2040s rather than
2025 [8], the target date of the Mectizan Donation Program [9]. This sole reliance on IVM has
other drawbacks, including the emergence of suboptimal responses to the drug in some O. vol-
vulus populations in Ghana and Cameroon [10,11] and IVM contraindications in people
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heavily co-infected with another filarial nematode, Loa loa, who are at risk of severe adverse
events [12,13].
One of the key goals of onchocerciasis research over several decades has been to identify a
drug with a good safety profile that can kill the adult stage of the parasite (a ‘macrofilaricide’).
At one time, moxidectin, a drug in the same class as IVM (the macrocyclic lactones), was con-
sidered to have macrofilaricidal potential [14]. However, several animal studies, including in
the natural Onchocerca ochengi system in cattle [15], have failed to demonstrate any significant
macrofilaricidal effects of moxidectin, although it suppresses Mf for longer than IVM after a
single dose [16,17]. Following successful Phase III trials that supported this superior microfi-
laricidal and sterilising effect [18], moxidectin has recently been approved by the US Food and
Drug Administration for use against onchocerciasis. Recent preclinical studies have provided
strong evidence that oxfendazole (a benzimidazole [19]) and ABBV-4083 (a derivative of tylo-
sin—a macrolide antibiotic targeting the obligateWolbachia endosymbiont found in many
filarial species [20]) have genuine macrofilaricidal activity. A third leading macrofilaricidal
compound, emodepside (a cyclooctadepsipeptide), is the focus of the current study.
The anthelmintic activity of a new N-methylated cyclooctadepsipeptide, PF1022A, the
parent compound of emodepside, was originally described against Ascaridia galli in chickens
[21]. PF1022A is a fermentation product of the fungus Rosellinia spp., found on the leaves of
Camellia japonica [22]. While PF1022A treatments of multiple host species resulted in good
efficacy against intestinal stages of a variety of nematodes, parenteral stages were not suffi-
ciently affected [23–25]. Therefore, to increase systemic exposure, two morpholine rings
were added to the depsipeptide structure, resulting in the semi-synthetic derivative, emodep-
side. Evaluation of emodepside revealed a broader spectrum of activity in vivo, including effi-
cacy against cerebral stages of Angiostrongylus cantonensis and muscle stages of Trichinella
spiralis, as well as against larval stages of intestinal nematodes deeply embedded in tissue,
such as Trichuris spp. [26,27]. Emodepside was also found to exhibit various antifilarial
effects against different stages of Acanthocheilonema viteae, Litomosoides sigmodontis and
Brugia malayi using theMastomys coucha rodent model [28,29]. Furthermore, it was highly
effective against Onchocerca spp. from cattle (adult Onchocerca gutturosa in vitro and Mf of
Onchocerca lienalis in a surrogate mouse model), although it was less potent against Brugia
pahangi [30].
In combination with praziquantel, emodepside was introduced into several veterinary mar-
kets across the world as Profender [26], the first topical dewormer for cats and as a tablet for
dogs. One of the key characteristics of emodepside is that it remains fully efficacious against
nematodes that are resistant to closantel, fenbantel, fenbendazole, levamisole and IVM in
sheep and cattle, suggesting that cyclooctadepsipeptides exhibit a novel mechanism of action
[31]. This was also confirmed in a multi-resistant hookworm isolate in dogs [32].
Latrophilins are classified as adhesion G protein-coupled receptors and latrophilin-1 is
localised both pre- and post-synaptically in neurons [33]. Lat-1-deficient Caenorhabditis ele-
gans was demonstrated to remain severely affected in locomotion and reproduction when
exposed to emodepside, while showing a drastically reduced inhibition of the pharynx [34].
Subsequently, the large-conductance calcium-dependent, voltage-gated potassium channel
SLO-1 was identified as essential for emodepside’s effects on the pharynx, motility and repro-
duction of C. elegans [35,36]. Using the Xenopus laevis oocyte expression system, it was dem-
onstrated that emodepside directly opens the C. elegans SLO-1 channel [37]. Furthermore, an
electrophysiological cross-phylum (nematode, arthropod and mammalian) comparison of the
mode of action of emodepside indicated that its anthelmintic activity derives from strong and
prolonged activation of nematode SLO-1 currents, not observed in the human channel [38].
Thus, based on its nematodicidal spectrum of activity [26], its strong activation of, and high
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affinity for, the nematode drug target SLO-1 over the mammalian ortholog [38,39], and more-
over, its resistance-breaking properties [31,32], emodepside is considered to be one of the
most promising developmental candidates for the treatment of human onchocerciasis and
soil-transmitted helminthiases [40–43].
The identification of slo-1 genes in all species across the phylum Nematoda gives hope for a
broad anthelmintic for human use. However, characterisation of several splice variants and
paralogues in some parasitic nematodes suggests that there are substantial differences in chan-
nel properties among species and lifecycle stages [37,44,45]. Here, we evaluate the macrofilari-
cidal activity of emodepside in the natural O. ochengi–cattle model.
Materials and methods
Ethics statement
The study design and the experimental procedures of the dose identification study in Germany
were approved by the responsible authorities (LANUV–Landesamt für Natur, Umwelt und
Verbraucherschutz NRW) under the reference number 200a166. All procedures performed on
cattle in Cameroon were equivalent to those authorized by a Home Office Project License
(Animals [Scientific Procedures] Act 1986) for related work on cattle in the UK. The study was
also approved by the University of Liverpool’s Animal Welfare Ethical Review Board and a
local, independent Animal Welfare Ethics Committee commissioned by the Cameroon Acad-
emy of Sciences.
Identification of slo-1 splice variants in O. ochengi
O. ochengi adult worms of both sexes were obtained from bovine skins purchased from
Ngaoundéré abattoir, Adamawa Region, Cameroon. Viable, isolated worms were transferred
into RNAlater (Ambion) to prevent RNA degradation and shipped on dry ice to the University
of Liverpool where they were stored at –80˚C. Worms were forwarded to Bayer, Germany, in
RNAlater on gel-ice packs (4–8˚C). Extraction of total RNA was performed using standard
molecular biology procedures [46]. Briefly, total RNA was extracted from one entire male
worm from which 1 μg of total RNA (DNase-treated) was reverse-transcribed to cDNA using
a (dT)30 primer and SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA).
We used a basic local alignment search tool (BLAST) approach to identify the slo-1 gene within
the O. ochengi genome and designed forward and reverse primers to amplify the full-length
open reading frame (ORF) by polymerase chain reaction (PCR). The gene was identified in
both O. ochengi genome assemblies available on the WormBase ParaSite (PRJEB1465 and
PRJEB1204) web platform [47,48]. Gene-specific primers located in the 3’ and 5’ untranslated
region (UTR) of the gene were designed using Primer3 software [49]. The gene-specific PCR
to obtain the full-length Ooc-slo-1 from O. ochengi cDNA was performed using Phusion poly-
merase (New England Biolabs, Ipswich, MA, USA) and primer pair NheI_Ooc-slo-1_F1
(GGCGGCTAGCAGGAAGAAAAGATGAGCGATGTAT) and XhoI_Ooc-slo-1_R1
(GGCGCTCGAGGACTGGCACAACAAATCATAGAA). The reaction conditions were:
98˚C for 60 s; 36 cycles of: 98˚C for 15 s; 55˚C for 30 s; 72˚C for 3.5 min; and 72˚C for 10 min.
Corresponding ORFs were sequenced and cloned into the pT7-TS transcription vector (pBlue-
script, Agilent, Waldbronn, Germany) for subsequent X. laevis oocyte experiments. Sequence
alignments of identified O. ochengi slo-1 splice variants with O. volvulus slo-1 splice variants
(WormBase entry OVO4127 a–d, f) were performed using the default parameters of the Multi-
ple Sequence Alignment tool MultAlin [50].
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Heterologous expression of Onchocerca spp. slo-1 splice variants and
assessment of emodepside sensitivity
Two identified O. ochengi slo-1 splice variants and five O. volvulus slo-1 splice variants were
expressed in laboratory-bred X. laevis oocytes (EcoCyte Bioscience, Dortmund, Germany)
for functional characterization. The cDNAs of five full-length O. volvulus splice variants
were synthesized in accordance with available sequences predicted from the O. volvulus
genome (WormBase entry OVO4127 a–d, f), while O. ochengi isoforms were amplified from
cDNA (see above). The coding sequences (CDS) of each splice variant was cloned into the
pT7-TS transcription vector (pBluescript) and integrity of the ORF was confirmed by Sanger
sequencing. The pT7-TS vector is designed to introduce X. laevis beta-globin 5’ and 3’UTR
to the insert sequence to enhance its expression in X. laevis oocytes. For all slo-1 splice vari-
ants, capped cRNAs were synthesized (T7 mMessage mMachine kit, Ambion, Austin, TX,
USA) from the linearized vectors containing the different slo-1 splice variants according to
the manufacturer’s protocol and cRNA samples were stored at –80˚C. Oocytes were ordered
from EcoCyte (Germany) and injected using standard procedures [51]. Oocytes were micro-
injected using a Roboinject automatic injection system (Multi Channel Systems, Reutlingen,
Germany) with 30 nL of cRNA solution (250 ng/μL) and then incubated at 18˚C in sterile-fil-
tered Barth solution containing: NaCl (88 mM), KCl (1 mM), NaHCO3 (2.4 mM), HEPES
(10 mM, pH 7.5), MgSO4�7H2O (0.82 mM), Ca(NO3)2�4H2O (0.33 mM) and CaCl2�6H2O
(0.41 mM), at pH 7.4, and supplemented with 20 μg/mL of kanamycin, 100 U/mL penicillin,
and 100 μg/mL streptomycin. Recordings were made 3–6 days post cRNA injection.
Electrophysiological recordings such as current-voltage curves (IVCs) were performed using
an automated two-electrode voltage-clamp AutoMate (HiClamp, multichannel system).
Oocytes were impaled with two electrodes filled with 3 M KCl. To determine the effect of
emodepside, cells expressing the different SLO-1 splice variants were clamped at –80 mV.
Data were recorded at a frequency of 5,000 Hz during clamping, with the membrane poten-
tial between –60 and +80 mV for 500 ms using voltage steps of 20 mV. Between individual
steps, the membrane potential was clamped to –80 mV for 1 s. All recordings were per-
formed at 18˚C ± 4˚C and cells were superfused with OR2 medium containing: NaCl (88
mM), KCl (2.5 mM), HEPES (5 mM), MgCl2.6H2O (1 mM) and CaCl2.2H2O (1.8 mM) at
pH 7.4. After initial recordings of IVCs, a perfusion with OR2 was performed for 1 min to
determine the basal expression level of Onchocerca spp. SLO-1 in each cell. Next, five con-
centrations of emodepside (0.3, 1, 3, 10 and 30 μM in 0.1% dimethyl sulfoxide; DMSO) were
tested on at least three cells per SLO-1 splice variant and IVCs measured after a 1 min incu-
bation in the drug. The analysis was done using the HiClamp data acquisition and analysis
software running under MATLAB (Mathworks Inc., Natick, MA, USA). Statistical analysis
was performed using either Prism (GraphPad) or Excel (Microsoft). Plots of the peak out-
ward currents at +20 mV (standardized to the current amplitude measured in OR2 buffer
only) as a function of the logarithm of the drug concentration yielded classical concentra-
tion–activation curves and were readily fitted by single Hill equations. Concentration-activa-
tion curves were fitted with the equation:
Y ¼ 100= 1þ 10HðlogEC50  XÞ
  �
where Y is the normalized response, logEC50 is the logarithm of the concentration of emo-
depside eliciting half-maximal current amplitude, X is the log of dose or concentration, and
H is the slope factor or Hill slope.
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Bioanalytics of emodepside
Bovine samples (EDTA-plasma, skin snips and nodules) were stored at –80˚C in Cameroon
and shipped according to international transportation guidelines on dry ice to Bayer, Ger-
many. Due to suspected contamination with other pathogens, samples required decontamina-
tion. Based on modified WHO guidelines for viral inactivation [52] and reports of virus
stability in fluids and solid media issued by the United States Army [53], decontamination of
samples was performed. Samples were thawed slowly in a microbiological safety cabinet and
the plasma samples were vortexed gently. Skin snips and nodules were homogenized in a Qia-
gen TissueLyser II (Qiagen NV, Hilden, the Netherlands) with stainless steel beads. Homoge-
nates were weighed and mixed with 4.5 volumes of a 0.5% collagenase solution (collagenase
from Clostridium histolyticum [>125 IU/mg] Merck KGaA, Darmstadt, Germany), then incu-
bated at 37˚C with orbital mixing at 140 rpm for 48 h.
Plasma samples, skin and nodule homogenates were precipitated in a 1:10 ratio with aceto-
nitrile using a vortex mixer at 150 rpm for 10 min, then centrifuged for 5 min at 14,000 rpm.
The supernatants were pipetted into gas-tight vials and incubated at 80˚C for 21 min to achieve
a core temperature of 80˚C for 10 min, then cooled to 4˚C in a water-ice bath. Finally, samples
were filtered using a cellulose sterile filter (S&S Spartan 13/30) into standard HPLC vials for
liquid chromatography–mass spectrometry analysis. For liquid chromatography on a C18 col-
umn, a water/methanol gradient (containing 10 mmol ammonium acetate and 0.1 mL/L
formic acid) was used. Quantification of emodepside was performed by tandem mass spec-
trometry on an API 5500 instrument (AB Sciex, Darmstadt, Germany) using the transition of
m/z = 1,120 ([M + H]+) to its product ion m/z = 343. The extraction procedure was validated
for plasma by concurrent recovery rates in the range 1–1,000 μg/L (n = 8, mean recovery 90%,
relative standard deviation [SD] 5.4%) and for nodules and skin extracts between 1 and 1,000
ng/mL (n = 10, mean 105%, relative SD 16.2%).
Dose identification in Holstein cattle
To ensure that doses of emodepside would be well tolerated in cattle in Cameroon, and that
any adverse effects would be manageable in the field, dose identification was first performed in
two female Holstein cattle (Bos taurus) 13–15 months old in Germany. Animals were from
Rinder Union West, 48147 Münster, Germany, and were kept in a pen in an outdoor climate
housing system of approximately 8 × 10 m in size in Hanscheider Hof, 51399 Burscheid, Ger-
many. Pens were equipped with a self-locking feeding fence, deep-straw bedding and an auto-
matic cup drinker system. Animals were offered fresh corn- and grass-silage once daily ad
libitum, drinking water from the onsite well and mineral licks ad libitum. Straw bedding was
refreshed at least weekly. Tolerability and pharmacokinetics (PK) of emodepside were assessed
after a single intravenous (IV) injection: emodepside (4.0% m/m in solketal) was administered
by constant infusion via the external jugular vein using disposable sterile IV catheters (Vasofix
Braunüle 14G, 2,2 × 50 mm, Braun, Germany), sterile syringes (Perfusor-Syringe 50 mL,
Braun, Germany), tubing systems (Braun Original-Perfusor-tubing, 150 cm, Luer Lock), and a
perfusion system (Braun Perfusor Space). Animal 1 received emodepside 2.17 mg/kg; animal 2
received emodepside 1 mg/kg. Safety and tolerability were assessed during and after each
administration. Animal 1 exhibited adverse effects and was stabilized with sedative (2 × 15 mg
xylazine hydrochloride IV), corticosteroids (300 mg prednisolone-succinate-Na IV; 200 mg
dexamethasone IV), glucose (750 mL glucose 5% IV), and saline (1.5 L sodium chloride 0.9%
IV). To determine the PK profile of emodepside and any possible influence of the drug on
blood glucose concentrations, blood samples were drawn before dosing and at 4 min, 8
min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, 32 h, 48 h, 72 h, 96 h and 168 h after
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administration. Samples for glucose determination were taken before dosing and at 15 min, 30
min, 1 h, 2 h, 3 h, 4 h, 6 h and 8 h after dosing, centrifuged at 10˚C (3,220 × g) for 10 min and
stored under cool conditions (<8˚C).
Modelling of single and multiple doses of emodepside for administration in
cattle
Emodepside exposure in cattle after repeated IV administration was simulated based on two-
compartmental evaluation of three PK profiles in zebu (Ngaoundéré Gudali) cattle (local
breed; Bos taurus indicus): a single dose of 0.15 mg/kg, two doses of 0.15 mg/kg each 24 h
apart, and a single dose of 0.75 mg/kg (75% of the maximum tolerated dose as a safety margin).
In this study, we refer to the lower doses (0.15 mg/kg, singly or repeated) as the “humanized
dose”. This is a plausible dose based on the human phase I trial data (in which single doses of
up to 40 mg, and twice-daily doses of 10 mg for up to 10 days, were administered [54]). Model-
ling and simulations were performed using Phoenix WinNonlin (Certara) version 6.4 or later.
A model using clearance and volume parameterization was produced to describe the concen-
tration–time data. Model fitting and parameter estimation was performed with the Gauss–
Newton algorithm and weighting with 1/(Yhat�Yhat). The obtained parameter estimates were
used as fixed input for the simulations of PK profiles in cattle after seven daily IV administra-
tions of 0.15 mg/kg or 0.75 mg/kg, respectively. Non-compartmental analysis of the simulated
PK profiles was also performed to assess the impact of emodepside accumulation and to com-
pare the efficacious exposure in cattle with the efficacious exposure in humans [54].
Dose confirmation in zebu cattle with single-high, single-low and two
consecutive low doses
The safety, tolerability and PK of low- and high-dose emodepside were confirmed in zebu
(Ngaoundéré Gudali) cattle at the Veterinary Laboratory of L’Institut de Recherche Agricole
pour le Développement (IRAD) at Wakwa (lat. 7˚12’33”N, long. 13˚34’20”E) near Ngaoun-
déré, Cameroon. Four non-pregnant, non-lactating cows naturally infected with O. ochengi
were purchased from farmers in the Vina Division of the Adamawa Region and acclimatized
at the IRAD Wakwa site for two weeks before the start of the trial. Cows were 3–6 years old
and weighed 185–300 kg. They were housed in a 35 m2 enclosure at night and fed with cotton
seed cake (2 g/kg bodyweight) in the morning before grazing them on a 1 ha Brachiaria ruzi-
ziensis paddock between 9 am and 4 pm daily. Water and salt were supplied ad libitum when
housed. Each cow was randomly allocated (by ear-tag number using an online research ran-
domizer [available at https://www.randomizer.org]) to receive a single low dose of emodepside
0.15 mg/kg, a single high dose of emodepside 0.75 mg/kg, a low dose twice (emodepside 0.15
mg/kg on two consecutive days), or vehicle only (solketal). Prior to treatment, the cows were
sedated with xylazine hydrochloride (Rompun). Verum or vehicle was administered IV into
the jugular vein using a perfusion apparatus (Braun Perfusor Space) following an identical pro-
tocol to the Holstein pre-study described above.
Selection of cattle for evaluation of efficacy of emodepside against O.
ochengi
Forty-two cows of the Ngaoundéré Gudali breed were purchased from local markets and
farms where O. ochengi infection is endemic, across the Adamawa Plateau in northern Camer-
oon. Sample size was in part dictated by the upper limit of onsite facilities, a constraint typical
of large-animal studies, and a group size of six (n = 7 here, permitting comparison of six dose
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or control groups) has been used effectively in previous drug studies in cattle [55,56]. Predeter-
mined inclusion criteria were an O. ochengi nodule load of�21, weight 200–400 kg, and age
3–10 years (estimated by dentition). Exclusion criteria were evidence of pregnancy and/or lac-
tation, poor body condition, suspected calcified O. ochengi nodules (abnormally hard on pal-
pation), a positive skin reactivity test for bovine tuberculosis, dermal signs of infection with
the bacterium Dermatophilus congolensis or heavy infestation with nodule-forming parasitic
mites (Demodex bovis). After purchase, the animals were transferred to the premises of L’Insti-
tut de Recherche Agricole pour le Développement, Regional Centre of Wakwa, where trans-
mission of O. ochengi is negligible. Health checks and routine vaccinations against endemic
diseases were completed at least one month before the start of the experiment. Animals could
drink from streams and lakes within a 2 km radius of sleeping pens, were free to graze by day
and were confined at night. Salt was provided ad libitum and a cotton seed cake supplement
was supplied at 200 g per 100 kg bodyweight during the study. Hay was provided during the
dry season, supplemented with wheat and maize bran each morning before the animals went
to graze. Herdsmen ensured animals did not enter zones of high parasite transmission.
Cattle were stratified by age, weight and dermal Mf load and randomly allocated (https://
www.randomizer.org) to six treatment groups (seven animals/group) as previously described
[56], such that the mean weight per group was 250–350 kg (group SD<50 kg) and the median
age per group did not differ by�1 year. By group, the geometric mean Mf load per 100 mg
skin ranged from 100 to 500 (Table 1); two animals found to be negative for skin Mf were dis-
tributed in different groups. Eighteen preselected nodules per animal were marked with tattoo
ink, and their positions were recorded on a hardcopy ‘hide map’ and by digital video [57]. All
assessments of drug efficacy were conducted by individuals blinded to the treatment groups.
The study was conducted unmasked. All study personnel provided a signed declaration to
conduct the study according to the specified protocol. Verum or vehicle was administered as
described in the dose confirmation study.
Measurement of blood glucose
Glucose concentrations were measured pre- and post-chemotherapy using venous blood,
which was analyzed in a test-strip assay (MediTouch 2 blood glucose monitor, Medisana,
Table 1. Characteristics of the treatment groups in cattle.
Group
abbreviation




Geometric mean Mf load (SD
factor), per 100 mg skin#
Animals lost during
experiment (cause, time)
PCBO Placebo (solketal), daily for 7
days�
290 ± 37 5 (3–10) 202 (17.8) 0
MRSM Melarsomine, 4 mg/kg, every
other day for 3 days
280 ± 33 5 (3–10) 335 (11.7) 0
EMO1L Emodepside, 0.15 mg/kg, single
dose
287 ± 32 5 (3–10) 278 (8.1) 0
EMO7L Emodepside, 0.15 mg/kg, daily
for 7 days
294 ± 40 5 (3–10) 122 (18.5) 2 (clostridial infection, day 21;
stolen, day 60)
EMO1H Emodepside, 0.75 mg/kg, single
dose
309 ± 49 5 (3–10) 473 (6.0) 1 (stolen, day 90)
EMO7H Emodepside, 0.75 mg/kg, daily
for 7 days
289 ± 29 5 (3–10) 195 (19.7) 0
�Volume administered was equivalent to that in the EMO7H group.
#Geometric mean is based on a log10(×)+1 transformation to include zero counts. Baseline data were acquired at day 14.
Mf, microfilariae; SD, standard deviation.
https://doi.org/10.1371/journal.ppat.1009601.t001
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Neuss, Germany). Both individual animal and group blood-glucose concentrations were com-
pared with a standard reference range for cattle (45–75 mg/dL [58]). To evaluate group-level
effects, 95% confidence intervals (CI) were calculated using the group mean, SD and sample
number for each group at each respective timepoint, with changes in blood glucose concentra-
tion considered significant if either the lower CI exceeded the upper limit of the standard refer-
ence range, or the upper CI was below the lower limit of the standard reference range.
Parasite enumeration and assessment of viability and fecundity
Tattooed nodules were removed under local anesthesia (lidocaine-epinephrine) on study days
-1, 90, 180–190, 270–290, 360 and 550 in a randomized order as previously described [57].
Nodules were trimmed of excess tissue and up to four nodules per animal were processed sepa-
rately as follows: (1) stored frozen at –80˚C for PK analysis (up to day 14 only); (2) injected in
toto with 10% neutral-buffered formalin and stored at 4˚C for histopathology (up to day 290
only); or (3) dissected immediately in phosphate-buffered saline to separate adult male and
female worms. The anterior end of the female worm (which even in viable specimens is the
only motile part of the parasite) was removed from the worm mass and incubated alongside
intact male worms for 30 min at 37˚C for visual motility assessment on a three-point scale
[59]. The remaining portion of the female worm mass was subjectively scored for fecundity on
a four-point scale (0, uteri empty or worm structure degraded; 1, low; 2, intermediate; 3, nor-
mal) by examining the uterine contents microscopically in situ. This was followed by a fully
quantitative embryogram to enumerate oocytes, embryonic stages and intrauterine Mf as
described previously [59].
Worms from a second unfixed nodule (at the same timepoints listed above) were subjected
to a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for metabolic
activity [59], in which the insoluble formazan product was dissolved in DMSO and quantified
colorimetrically at 620 nm in a microplate reader (model LT4500, Labtech, Heathfield, East
Sussex, UK). Finally, dermal microfilarial densities were determined by incubation of skin
biopsies (in triplicate per animal per timepoint) and normalized to 100 mg skin [59].
Histopathology
Nodules for histopathology (n = 72) were collected up to day 290, after which few were avail-
able in the melarsomine (MRSM) group. For consistency, nodules were taken from the same
three animals in each experimental group at each timepoint. Formalin-fixed nodules were
embedded in paraffin, sectioned, and stained with hematoxylin and eosin or Giemsa as previ-
ously described [57,60] or with Lendrum’s carbol chromotrope [61] to specifically stain
eosinophils.
Histological sections of nodules were scored by a single observer blinded to treatment
group using the form proposed by Striebel [62], which was developed based on observations of
O. volvulus (human) and Onchocerca gibsoni (bovine) nodules. In the current study, O. ochengi
nodules were graded by applying a similar system in which the integrity of five structures or
organs (cuticle, hypodermis, longitudinal muscle, pseudocoelomic cavity and gut) were classi-
fied through microscopical assessment of specific anatomical features (e.g., vacuoles in the
hypodermis or host cells visible in the pseudocoelomic cavity) according to the categories in
Table A in S1 Text. These grades were used to assign a pathology score for each aspect of para-
site anatomy examined. Scores for all five structures or organs were then added together to
produce a cumulative overall score, with a minimum score of 5 for parasite sections judged to
be healthy across all five structures or organs. Since parasite sections showing extensive dam-
age across all five anatomical regions could score a maximum of 15, sections containing
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cuticular debris only, or where parasites were unidentifiable in the section, were allocated a
total score of 16. Where sections of male worms were present in the nodule these were scored
separately to the females. Some sections contained more than one conjoined nodule. In these
cases, females were also scored and recorded individually.
Cellular infiltrates within nodules, specifically polymorphonuclear cells (PMNs), were also
assessed. Neutrophil and eosinophil counts were performed under oil immersion in cellular
infiltrates immediately adjacent to sections of parasites on Giemsa-stained sections. A mini-
mum of 200 cells were counted for each section and expressed as cells per high-power field. In
sections containing no parasites, PMN counts were recorded if present in sufficient numbers.
Histology sections stained by Lendrum’s method [61] were examined to quantify eosinophils.
The PMNs were counted in cellular infiltrates immediately adjacent to sections of parasites as
before (minimum of 100 differentiated cells/section).
The effect of different treatments relative to either (a) no treatment controls or (b) pre-
treatment observations of parasite integrity was analyzed using linear mixed effects models
with the nonlinear mixed effects model package in R [63,64]. Overall scores for parasite integ-
rity were modelled as the response variable compared with (a) treatment groups for each time-
point and (b) different timepoints for each respective treatment group. In both cases, animal
identity was modelled as a random effect to account for repeat observations taken from the
same individual, and results were adjusted using a post-hoc Bonferroni correction for multiple
comparisons. Similarly, to assess the effect of different treatments on cellular infiltrates over
time, total PMN or eosinophil counts per high-power field and eosinophils as a percentage of
the total PMN population were each modelled as explanatory variables compared with (a)
treatment groups for each timepoint and (b) different timepoints for each respective treatment
group.
Pharmacokinetic–pharmacodynamic modelling of the effect of emodepside
on O. ochengi
For the PK mean model, the PK of emodepside was modelled using a closed-form, two-com-
partment IV model according to Eq 1.
csd tð Þ ¼ dose � c0 � exp   ke � tð Þ � 1þ delta � exp þke � f � tð Þð Þ ð1Þ
with ke, f and delta being parameters describing the distribution and elimination phase, and c0
being a proportionality factor for the dose.
The multiple IV dose was modelled as an additive single-dose, two-compartment model
according to Eq 2.
cmd tð Þ ¼
X7
i¼1
t   i � tD > 0?csd t   i � tDð Þ : 0 ð2Þ
with i as index of doses (1 to 7), and tΔ the difference in time between consecutive doses (here
24 h).
Parameters describing distribution and elimination of emodepside were fitted to the
observed data of all dose steps and animals together using the optim fit function of R and
the ‘L-BFGS-B’ method [65] without box constraints. From the observed data, the maximal
observed concentration and the corresponding timepoint were extracted. The terminal half-
life was calculated from the last three datapoints. The corresponding mean values were derived
from the compartmental model parameters.
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For pharmacokinetic/pharmacodynamic (PK/PD) modelling, we assumed a direct propor-
tionality between drug concentration and drug effect according to Eq 3:
E ¼ m � C þ E0 ð3Þ
with E: PD endpoint, E0 the base (placebo) endpoint, m: a proportionality factor, and C the
emodepside exposure.
Here, the null hypothesis, H0, is that the parameter m is not different to 0. If H0 can be
rejected, a concentration-dependent effect of emodepside can be assumed. The alpha level
selected for statistical significance was 5%. We considered three PD endpoints, a) uterine con-
tents (with oocytes, developing embryonic stages, normal intrauterine Mf and degenerate
intrauterine Mf considered separately), b) skin Mf load, and c) male and female motility (sepa-







� ti   ti  1ð Þ ð4Þ
per individual treated animal. To increase the robustness of the analysis, only animals present-
ing a skin Mf load of�100/100 mg skin at day -1 were included.
The same principle was applied to the analysis of the uterine contents. In order to test a
dose-dependent effect, and an effect over placebo, the log load of uterine contents or Mf was
used as the PD endpoint E in Eq 3, and exposure C was the sum of doses. Over all doses and
individual animals, an effect size (m) and corresponding statistics were calculated using R’s lm
function [66].
The second class of PD endpoint considered was worm motility, which was recorded as a
three-class categorical variable and quantified here as a fraction of normal worm motility.
First, a linear model of decrease in motility per dose group was established with a study-wide
mean motility at day –1:
motilitydose group;t ¼ mean motilityday  1
� �
  slopedose group � t ð5Þ
Then, Eq 3 was applied for the PD endpoint ‘slopedose_group’ and the exposure as the sum of
doses (performed separately for male and female worm motility).
All raw data underpinning this study are publicly available at Dryad (https://datadryad.org/
stash) with the identifier doi:10.5061/dryad.vhhmgqns0 [67].
Results
Identification of two slo-1 splice variants from O. ochengi adult worms
Using cDNA from O. ochengi samples, we were able to verify expression of the major emodep-
side target SLO-1 in O. ochengi adult male worms. In total, two different full-length CDSs of
the O. ochengi slo-1 gene, both 3,360 base pairs (bp) in length, were amplified and Sanger
sequenced (splice variant a, GenBank: MW039265; splice variant b, GenBank: MW039266).
The predicted amino acid sequences (1,119 amino acids) of both CDS were aligned against
CDS of the O. volvulus slo-1 gene, which has five predicted full-length splice variants
(WormBase CDS OVO4127a –d and f) and one truncated splice variant (WormBase CDS
OVO4127e) (Fig A in S1 Text). The two O. ochengi SLO-1 sequences shared the highest simi-
larity with the O. volvulus SLO-1 splice variants a and b, respectively. The first O. ochengi
sequence and O. volvulus SLO-1 splice variant a differ only in a single amino acid at position
658 (Arg to Lys) (Fig B in S1 Text). For the second identified O. ochengi sequence and its
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homologous O. volvulus splice variant b, two amino acid changes were identified at positions
658 (Arg to Lys) and 711 (Arg to Cys) (Fig C in S1 Text). The sequence alignments of the iden-
tified O. ochengi SLO-1 sequences with the corresponding O. volvulus splice variants revealed
that SLO-1 is highly conserved between both species and that at least two SLO-1 splice variants
are expressed in O. ochengi adult males.
Functional expression of Onchocerca spp. isoforms in Xenopus laevis
oocytes
To investigate potential species- and isoform-specific differences in SLO-1 regarding emodep-
side sensitivity, we expressed the two identified O. ochengi splice variants and all five full-
length O. volvulus splice variants heterologously in X. laevis oocytes to compare their respon-
siveness to emodepside. All heterologously expressed SLO-1 splice variants were able to form
functional homomeric channels in the oocytes as shown by electrophysiological recordings.
For SLO-1-expressing cells, an average baseline current of<3 μA was typically measured
when cells were clamped at +20 mV under control conditions. When exposed to increasing
concentrations of emodepside (0.3, 1, 3, 10 and 30 μM), no current increase effect was visible
at concentrations below 3 μM. Maximal peak currents measured at +20 mV and 30 μM emo-
depside ranked from 19.1 μA for O. volvulus splice variant f to 39.9 μA for the O. volvulus
SLO-1 splice variant a. Generated normalized concentration-response curves (Fig 1) revealed
no notable differences in EC50 values (average EC50 ~7.8 μM) among any of the homomeric
channels, indicating similar emodepside sensitivity of the drug target in both species and
among all splice variants investigated (Table 2).
Fig 1. Emodepside sensitivity of Onchocerca ochengi and Onchocerca volvulus SLO-1 splice variants.Onchocerca spp. SLO-1 splice variants were
heterologously expressed in X. laevis oocytes to determine species- and splice variant-specific effects of emodepside. All seven SLO-1 splice variants
were able to form functional homomeric ion channels and changes in current could be measured with an electrophysiological two-electrode, voltage-
clamp approach with oocytes exposed to increasing concentrations of emodepside (0.3, 1, 3, 10 and 30 μM). For each splice variant at each emodepside
concentration, 5–7 oocytes were tested from a single pool of transfected cells to generate biological replicate data; the experiment was performed
once. Datapoints are the mean values of the replicates at each emodepside concentration; error bars are standard error of the mean. Normalized
concentration–response curves were fitted using the Hill equation. No statistical comparisons were made. Details of the DNA preparation, transfection,
voltage clamp procedures and analyses are in the Materials and methods section. A Normalized concentration response curves for the two identifiedO.
ochengi splice variants (red) and their two homologous O. volvulus splice variants a and b (blue). B Normalized concentration response curves for all O.
volvulus full-length splice variants a–d, and f. Ooc_,Onchocerca ochengi; Ovo_,Onchocerca volvulus; SEM, standard error of the mean.
https://doi.org/10.1371/journal.ppat.1009601.g001
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Pharmacological effects of emodepside administration in cattle
Following perfusion in two Holstein cattle (perfusion rate: 45.2 mg/min; respiration 1.13 mL/
min) of 2.17 mg/kg emodepside, treatment of the first animal needed to be discontinued due
to severe generalised muscle tremor, salivation and tachycardia. As this animal was stabilised
with glucose, blood samples for determination of glucose concentrations were not taken after
perfusion and it recovered fully after 7 h. The second animal was perfused with a total dose of
1 mg/kg emodepside (perfusion rate: 22 mg/min; respiration 0.55 mL/min). During the appli-
cation, its heart rate peaked at 140 beats per minute (bpm), then stabilised at approximately
108 bpm by the end of the perfusion. Salivation and slight muscle tremors were observed for
approximately 1 h after application prior to full recovery of the animal. The perfusion of 1 mg/
kg emodepside provoked a slowly increasing moderate hyperglycaemia, which peaked at ~12
mmol/L from 3–8 h post-application, with levels reverting to normal (4.33 mmol/L) after 24 h.
Administration of xylazine for sedation at 6–8 h during skin biopsies may also have contrib-
uted to hyperglycaemia.
In the Cameroon pre-study in four zebu (Ngaoundéré Gudali) cattle, mild muscular trem-
ors and salivation were observed over a period of 1 h following drug administration at the
lower dose (0.15 mg/kg emodepside; perfusion rate, 0.6 mg/min or 0.07 mL/min). However,
no salivation and only very transient muscular tremors were apparent after a second low-dose
(0.15 mg/kg) treatment without xylazine sedation. Heart rate was mildly affected by the high-
dose (0.75 mg/kg) treatment, increasing from 72 to 80 bpm at 6 h post treatment, which was
maintained over the next three days before returning to normal on day 4. Rumen contraction
increased from 1 contraction/min with both the low-dose and high-dose treatments to 1.5 and
2 contractions/min, respectively, over the next four days after treatment. Temperature and
respiratory rates were not affected. High-dose treatment provoked a rise in blood glucose con-
centration to 158–200 mg/dL 8 h after treatment, which dropped to 61 mg/dL (within the nor-
mal range) by 24 h. A similar rise in glucose level was observed with the low-dose treatments.
Modelling of single and multiple humanized or high doses of emodepside
for administration in cattle
The PK profile of emodepside in plasma samples after administration to Holstein cattle was
obtained via the jugular vein at concertinaed intervals from 4 min to 168 h. The two-compart-
mental PK model predicted an initial plasma concentration of 120 μg/L in the low-dose
(“humanized”) group (0.15 mg/kg) and ~2,400 μg/L in the high-dose group (0.75 mg/kg) (Fig
D[a] in S1 Text). Double treatment of low-dose emodepside at 24-h intervals was predicted to
Table 2. Emodepside sensitivity of Onchocerca ochengi and Onchocerca volvulus SLO-1 splice variants. TwoO. ochengi and fiveO. volvulus splice variants were heter-
ologously expressed in Xenopus laevis oocytes and exposed to increasing concentrations of emodepside. Concentration-dependent changes in electric current were mea-
sured and concentration-response curves were generated. The EC50 value is the emodepside sensitivity of each SLO-1 splice variant.
Species SLO-1 splice variant Length (aa) Emodepside sensitivity
EC50 (μM) Standard error (μM)
O. ochengi a 1,119 8.1 ± 0.75
b 1,119 7.7 ± 0.52
O. volvulus a 1,119 7.4 ± 1.12
b 1,119 7.8 ± 1.04
c 1,104 7.8 ± 1.21
d 1,104 7.8 ± 1.20
f 1,143 8.4 ± 1.07
https://doi.org/10.1371/journal.ppat.1009601.t002
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ensure that a minimal plasma level of 5 μg/L (reached with the single low-dose treatment at 24
h) would be maintained for up to 72 h (Fig D[b] in S1 Text). Simulations of seven consecutive
daily doses of emodepside were generated based on the obtained PK parameters for 0.15 mg/
kg and 0.75 mg/kg. The concentration–time profiles (Fig D[a] in S1 Text) and non-compart-
mental analysis results (Table B in S1 Text) predicted no relevant accumulation of the peak
concentration (Cmax) and only moderate accumulation of the area under the curve (AUC)
between day 1 and the steady state of daily emodepside treatment. Based on these observations,
the following low- and high-dose emodepside regimens and controls were selected for com-
parison in the main trial: a single dose of emodepside 0.15 mg/kg (EMO1L), or of emodepside
0.15 mg/kg daily for seven days (EMO7L); a single dose of emodepside 0.75 mg/kg (EMO1H),
or of emodepside 0.75 mg/kg daily for seven days (EMO7H); a placebo control (PCBO) of
solketal daily for seven days; and a positive control of MRSM 4 mg/kg every other day for
three days.
Emodepside distribution in plasma and skin following single and multiple
humanized or high doses
In the main trial in Cameroon, it was prespecified that after inclusion, animals could only be
excluded from the study on health grounds. None were excluded but three animals were lost
to the experiment for reasons unrelated to the drug treatments (Table 1). As this occurred
after the treatment regimens had been completed, data for these animals were included in the
PK analysis and the PD analysis for dermal Mf load. A two-compartment model was fitted to
the observed plasma concentrations of emodepside; AUC, terminal half-life (t½), Cmax, and the
time taken to reach Cmax (Tmax) were derived from the PK model then compared with the
observed Cmax and Tmax (Table C in S1 Text). In the single dose groups (EMO1L [0.15 mg/
kg–“humanized”] and EMO1H [0.75 mg/kg]), the observed Cmax was usually apparent from
the first sampling (5 min). The terminal half-life was derived from observed data and aggre-
gated through the PK model to approximately 106 h. Fig 2 displays the observed plasma con-
centration at different dose steps for individual animals and the respective mean PK model.
The emodepside concentration in the skin varied substantially. On 54 occasions, skin and
plasma concentrations were measured on the same study day. Although the median ratio
between skin and plasma was approximately 1.1, it ranged from 0.03 to 93 (Fig E in S1 Text).
Effects of emodepside on blood glucose
Observed changes in blood glucose are summarised in Fig 3. Concentrations for individual
animals varied considerably between individuals, groups, and over time. Increases in serum
concentration following commencement of treatment were observed in animals in all experi-
mental groups for 6–24 h before returning to baseline levels. These increases were significantly
above the standard reference range for cattle (45–75 mg/dL [58]) at the group level following
MRSM treatment at 5 and 30 min and 2 h; both low- and high-dose single emodepside groups
(EMO1L and EMO1H, respectively) at 30 min, 2 and 6 h; and in the high-dose multiple emo-
depside group (EMO7H) at 2 h following treatment commencement (Fig 3).
Effects of emodepside on microfilarial density and embryogenesis
Sampling of skin Mf during chemotherapy was concertinaed to ensure that early effects of
emodepside (i.e., within the first three months) on this parasite stage were captured in detail
(Fig F in S1 Text). Mean Mf levels were reduced by 10–1,000-fold in the high-dose groups
(EMO1H and EMO7H) within seven days, whereas EMO7L took 14 days to reach a > 10-fold
decrease and EMO1L never attained a reduction of this magnitude (Fig 4). For placebo
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(PCBO), mean Mf densities remained above 1,000/100 mg skin until year 2, after which they
declined to ~400 Mf/100 mg skin. Despite this natural reduction in Mf levels in the absence of
treatment, hierarchical clustering analysis placed PCBO as an outgroup and clustered MRSM
and EMO7H together (Fig 4); these two groups exhibiting the most sustained declines in Mf
densities. However, the kinetics of Mf reduction showed important differences between these
two groups, with a slow but consistent decline in MRSM leading to complete clearance after
one year, compared with a sharp initial effect of chemotherapy in the first few weeks followed
by a partial recrudescence from 10 months with EMO7H (Fig 4). Although recoveries
approaching pre-treatment levels were observed as early as day 90 in EMO7L and EMO1H,
Fig 2. Observed plasma PK (concentration vs time curves) for four emodepside dose steps in zebu (Ngaoundéré Gudali) cattle (B. t. indicus). Dose
groups were intravenous emodepside: A 0.15 mg/kg/day on day 0. B 0.15 mg/kg/day on days 0–6. C 0.75 mg/kg/day on day 0. D 0.75 mg/kg/day on
days 0–6. Emodepside concentration in plasma was determined by tandem mass spectrometry using serial dilutions of single samples per animal (n = 7
per dose group) at each timepoint. Symbols represent observations for individual animals; the lines represent the PK model of emodepside for that
dosing regimen. Data are from a single study. No statistical comparisons were made.
https://doi.org/10.1371/journal.ppat.1009601.g002
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the reductions compared with baseline at 12 months for EMO1H and EMO7H were 79% and
87%, respectively, and by 18 months had reached 91% and 94%, respectively.
The effects of emodepside on oocyte numbers were apparent at day 90 with all regimens,
with recoveries to PCBO levels at day 550 in the single-dose groups contrasting with extirpa-
tion of oocytes in the multiple-dose groups (Fig G[a] in S1 Text). A clear impact on developing
embryonic stages was also observed at day 90 in the multiple-dose groups and they were virtu-
ally eliminated by these regimens by day 550 despite an intervening period of recovery (Fig G
[b] in S1 Text). The pattern for intrauterine Mf largely mirrored the effects seen on the earlier
stages, in that the multiple-dose groups cleared normal Mf from the uteri by day 550, unlike
the single-dose regimens (Fig G[c] in S1 Text). In the high-dose groups, numbers of degener-
ated Mf increased earlier (at day 90) than with the low-dose regimens (at day 185) (Fig G[d] in
Fig 3. Blood glucose concentrations observed pre- and post-treatment commencement with emodepside by experimental group in zebu
(Ngaoundéré Gudali) cattle (B. t. indicus). Glucose concentration in venous blood was determined by test strip assay (MediTouch 2 blood glucose
monitor, Medisana, Neuss, Germany). Treatment groups were single dose, or seven daily doses, of emodepside at 0.15 mg/kg (EMO1L, EMO7L) or 0.75
mg/kg (EMO1H, EMO7H), placebo (PCBO [solketal]) daily for seven days, and melarsomine (MRSM) 4 mg/kg every other day for three days as a
positive control. Points represent single observations in individual animals. Bars and whiskers represent group means with 95% CI. Normal distribution
was assumed because of the even distribution of individual blood glucose values above and below each group mean at each timepoint. The broken
horizontal line represents the standard reference range for bovine blood glucose concentrations. Timepoints where the group-level blood glucose 95%
CI was elevated above this range are marked with an asterisk. No formal statistical comparisons were made. EMO1H, emodepside, 0.75 mg/kg, single
dose; EMO7H, emodepside, 0.75 mg/kg, daily for seven days; EMO1L, emodepside, 0.15 mg/kg, single dose; EMO7L, emodepside, 0.15 mg/kg, daily for
seven days; MRSM, melarsomine, 4 mg/kg, every other day for three days; PCBO, placebo.
https://doi.org/10.1371/journal.ppat.1009601.g003
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S1 Text). Overall, the embryotoxic effects of emodepside were observed much later in the
experiment than for the positive control (MRSM).
Effects of emodepside on adult worm fecundity, viability and nodular
infiltrates
Female worm motility was reduced to zero by day 90 in all nodules recovered from MRSM
(Fig H[a] in S1 Text). In contrast, no dose of emodepside achieved this level of motility inhibi-
tion, although female worms recovered from 6/7 animals in the EMO7H group displayed
motility scores of 0 at day 550 (Fig H[b] in S1 Text). At the same timepoint, differences in
MTT reduction between MRSM and EMO7H were more marked; while no intact worms were
recovered from the former (Fig I[a] in S1 Text), female worms assayed from 4/7 animals in
EMO7H exhibited normal metabolism (Fig I[b] in S1 Text). However, female fecundity was
profoundly affected by all doses of emodepside by the end of the experiment, with EMO1L,
EMO7L and EMO7H displaying scores of<0.2 at day 550 (Fig J in S1 Text). Effects of emo-
depside on the motility of adult male worms appeared to be more limited than for females (Fig
K in S1 Text).
Histopathological analysis of nodules supported the direct observations of the adult para-
sites. A total of 72 nodules were taken from 18 animals across four timepoints (up until day
290) for histological assessment, yielding 77 parasite sections (62 females and 15 males;
Table D in S1 Text). Twelve sections contained either cuticular debris only or no identifiable
parasites (e.g., Fig 5B), including two nodules removed pre-treatment from animals in MRSM
and EMO1H, respectively. Data for these two nodules were excluded from subsequent analy-
ses. Overall, the analysis of parasite integrity based on cumulative scores indicated that worm
sections present in MRSM nodules had significantly higher pathology scores than PCBO
Fig 4. Mean dermal microfilarial density (n per 100 mg skin) in zebu (Ngaoundéré Gudali) cattle (B. t. indicus) treated with emodepside or
melarsomine compared with placebo. Mean dermal microfilarial density was determined by incubation of skin biopsies (in triplicate per animal, per
timepoint) normalized to 100 mg skin [59]. Mean density values are shown at each timepoint in each treatment group (n = 7 per group) and are color-
coded by quantile, from pale yellow (low microfilarial density) to dark red (high microfilarial density). The dendrogram was created by hierarchical
clustering based on Euclidean distance between mean dermal microfilarial density profiles and indicates the degree of similarity between treatments
based on the in vivo response over time. No between-group statistical comparisons were made. EMO1H, emodepside, 0.75 mg/kg, single dose; EMO7H,
emodepside, 0.75 mg/kg, daily for seven days; EMO1L, emodepside, 0.15 mg/kg, single dose; EMO7L, emodepside, 0.15 mg/kg, daily for seven days;
MRSM, melarsomine, 4 mg/kg, every other day for three days; PCBO, placebo.
https://doi.org/10.1371/journal.ppat.1009601.g004
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(P<0.05) at all post-treatment timepoints (Tables D and E in S1 Text; Fig 5). Scores also
increased significantly in MRSM worm sections for all post-treatment timepoints when com-
pared with pre-treatment scores within this group (Fig 5). However, no significant effect of
emodepside on worm integrity across the four dosing groups was apparent (Fig L and Table F
in S1 Text).
Fig 5. Histopathology of Onchocerca ochengi nodules treated with emodepside. Parasite sections were scored according to Striebel [62]. Scoring was
based on the overall condition of cuticle (Cu), hypodermis (Hy), longitudinal muscle (Lo), pseudocoelomic cavity (Ps), and gut (Gu; when present in
section). Age, reproductive status and nodular environment were also assessed. Micrographs (scale bars, 100 μm) show representative sections for
experimental groups at day 290 for: A Placebo (PCBO), showing transverse and oblique sections of a viable (animal ID B0406; score 7), non-productive
female. Solid arrow denotes debris within the uterine body. B Melarsomine (MRSM), showing a degenerate nodule composed predominantly of
collagen with foci of perivascular fibroblasts and polymorphonuclear cells. No evidence of parasites is present within the section (animal ID B0435;
score 16). C High-dose emodepside (EMO7H), showing multiple transverse sections of a viable (animal ID B0734, score 7), non-productive female in a
nodule with moderate polymorphonuclear cell infiltrate. Open arrow denotes eosinophilic Splendore–Hoeppli deposits. D Plots show cumulative
histopathological scores (across worm tissues and organs) by experimental group and timepoint (see Materials and methods for scoring procedure).
Datapoints are from a single nodule from different animals at each timepoint and include scores for male worms, where observed in nodules (Table D
in S1 Text). EMO1H, emodepside, 0.75 mg/kg, single dose; EMO7H, emodepside, 0.75 mg/kg, daily for seven days; EMO1L, emodepside, 0.15 mg/kg,
single dose; EMO7L, emodepside, 0.15 mg/kg, daily for seven days; MRSM, melarsomine, 4 mg/kg, every other day for three days; PCBO, placebo.
https://doi.org/10.1371/journal.ppat.1009601.g005
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Regarding host cell infiltrates within nodules, PMN numbers increased in EMO7L and
EMO1H over time, although statistical significance was not achieved in either case (Fig M and
Table G in S1 Text). No such trend was observed in EMO7H, although there were confound-
ing effects of exceptionally high pre-treatment PMN counts in this group. In EMO7L and
EMO1H, the proportion of eosinophils within the intranodular PMN populations decreased
significantly over time (Fig N and Table H in S1 Text).
PD modelling of the effect of emodepside on O. ochengi
We tested the hypothesis that emodepside had dose-dependent effects on dermal Mf density
and adult worm motility. The variability of the data required a robust approach to aggregate
individual observations. Therefore, we calculated the integral of the curve that describes Mf
density over time, denoted here as the Mf load. In comparison with MRSM, the emodepside
groups displayed higher variability in Mf load, although EMO7H achieved a similar median
reduction (97%) to MRSM (96%) (Fig 6). Notably, the single-dose groups (EMO1L and
EMO1H) exhibited reductions in Mf load of only ~70%, whereas EMO7L attained a reduction
of 86% (Fig 6). To analyse the relationship between Mf load and emodepside dose, a linear
model of the sum of drug doses and log observed Mf load was developed, which demonstrated
a significant negative association between these variables (P = 0.0042). Surprisingly, applying
Fig 6. Dermal microfilarial load distribution (area under the curve [load�time]) by treatment group in zebu (Ngaoundéré Gudali) cattle
(B. t. indicus). Dermal microfilarial density was determined at each timepoint by incubation of skin biopsies (in triplicate per animal at each
timepoint), normalized to 100 mg skin [59], then used to estimate total area under the load�time curve. The boxplot is ordered by dose steps of
emodepside (grey shading). The thick bar is the median, the limits of each box are the interquartile range, the whiskers are the smallest/largest
value within 1.5× the interquartile range, and the open circles are outliers. The placebo control and melarsomine (positive control) are shown
in orange and black, respectively. Median microfilaria load per treatment group as a proportion of placebo (normalized to 100%) is shown
above the plot. No between-group statistical comparisons were made. EMO1H, emodepside, 0.75 mg/kg, single dose; EMO7H, emodepside,
0.75 mg/kg, daily for seven days; EMO1L, emodepside, 0.15 mg/kg, single dose; EMO7L, emodepside, 0.15 mg/kg, daily for seven days; MF,
microfilariae; MRSM, melarsomine, 4 mg/kg, every other day for three days; PCBO, placebo.
https://doi.org/10.1371/journal.ppat.1009601.g006
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the same approach to the impact of emodepside on counts for uterine contents (oocytes, devel-
oping embryonic stages and intrauterine Mf) did not reveal a significant overall dose-depen-
dent effect. However, the AUC for all embryonic stages was significantly reduced in the
EMO7L group (P = 0.048 compared with P = 0.005 for MRSM) (Fig 7).
Adult female worm motility was highly variable across the six treatment groups at day −1,
ranging from 85% to 43% (overall mean 64%; Table I in S1 Text). Moreover, in PCBO over
time, the lowest recorded motility was 40% (at day 275). This variation reflects the natural
range of nodule (and therefore worm) ages between animals, with some nodules containing
senescent individuals. Therefore, a linear model was built on the assumption that the initial
motility value was 64% across all groups and decreases linearly over time. The model clearly
demonstrated that the slope (decrease of motility over time) is significant (P<0.05) for all
groups except PCBO, and the effect increased with dose (Fig 8). Male worm motility on day –1
Fig 7. Distribution of counts for uterine contents at different dose steps. (A) oocytes, (B) all developing embryonic stages, (C) normal, and (D)
degenerated intrauterine microfilariae in cattle treated with emodepside or melarsomine compared with placebo. Counts for uterine contents were
determined in samples from each animal (n = 7 animals per treatment group), then used to estimate total area under the load�time curve. The boxplot is
ordered by dose steps of emodepside (grey shading). The thick bar is the median, the limits of each box are the interquartile range, the whiskers are the
smallest/largest value within 1.5x the interquartile range, and the open circles are outliers. The placebo control and melarsomine (positive control) are
shown in orange and black, respectively. EMO1H, emodepside, 0.75 mg/kg, single dose; EMO7H, emodepside, 0.75 mg/kg, daily for seven days;
EMO1L, emodepside, 0.15 mg/kg, single dose; EMO7L, emodepside, 0.15 mg/kg, daily for seven days; MRSM, melarsomine, 4 mg/kg, every other day
for three days; PCBO, placebo.
https://doi.org/10.1371/journal.ppat.1009601.g007
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was uniformly high (classified as normal in all cases), while post-treatment data were missing
in MRSM, presumably due to the rapid macrofilaricidal activity of melarsomine on male
worms migrating between nodules (Table I in S1 Text). The onset of a reduction in male
motility was late in the emodepside groups (day 360) and only EMO7H showed a significant
decrease (Table I in S1 Text). While the reduction in male motility was not significant in
the other emodepside groups individually, the decrease was significantly related to dose
(P = 0.003); i.e., a higher overall dose results in a greater decrease in male motility (Fig O in
S1 Text).
Discussion
Here, we demonstrate that emodepside rapidly reduces the density of skin Mf, suppresses
female fecundity for at least 18 months, and (after multiple applications of a high dose) induces
partial macrofilaricidal effects, predominantly against females. To maximise the predictive
power of this preclinical study for assessing the efficacy of emodepside against human oncho-
cerciasis, three key steps were taken to validate the bovine screening system. First, the
Fig 8. Linear model describing the relationship between change in adult female worm (Onchocerca ochengi)
motility over time and total emodepside dose. The anterior end of the female worm was removed from the worm
mass and incubated alongside intact male worms for 30 min at 37˚C for visual motility assessment on a three-point
scale [59]. A linear model of worm motility over time for a given treatment group was estimated and repeated for each
group; the slope β for each group is reported in this figure. The null hypothesis was β = 0, and t statistics were used to
test and reject the null hypothesis and to estimate the P value. Datapoints are mean values and error bars represent
SEM. Dashed lines in red indicate the mean ± SEM for the positive control (MRSM). A regression model of the
relationship between dose and decrease in motility (black line) indicated there was a non-significant trend between
dose and treatment effect. EMO1H, emodepside, 0.75 mg/kg, single dose; EMO7H, emodepside, 0.75 mg/kg, daily for
seven days; EMO1L, emodepside, 0.15 mg/kg, single dose; EMO7L, emodepside, 0.15 mg/kg, daily for seven days;
MRSM, melarsomine, 4 mg/kg, every other day for three days; PCBO, placebo; SEM, standard error of the mean.
https://doi.org/10.1371/journal.ppat.1009601.g008
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pharmacological sensitivity of SLO-1 isoforms from the cattle parasite, O. ochengi, was demon-
strated to be equivalent to that of the human parasite, O. volvulus. Second, modelling of single
and multiple humanized doses was performed using the IV route in cattle to ensure that PK/
PD in this large animal system was comparable to the anticipated emodepside distribution in
humans (i.e., overall exposure in blood including bound and unbound drug). However, we
acknowledge that the rate of onset of systemic blood exposure would have been faster, and the
Cmax higher, in cattle compared with humans due to IV versus oral routes of administration,
respectively. Finally, the maximum tolerable dose for Holstein cattle determined in Germany
(emodepside 1 mg/kg with solketal as vehicle) was confirmed in the local breed of zebu
(Ngaoundéré Gudali) cattle at the study site in Cameroon, although as a safety margin, only
75% of this dose was administered because of the increased environmental stresses on cattle in
the tropics.
As was expected from prior in vitro and in vivo data on the effects of emodepside onOncho-
cerca spp. and other filariae [28–30,68], the drug exhibited dose-dependent efficacy against
both Mf and adult worms. The kinetics of Mf clearance in the first few days after treatment at
the higher dose were similar to those observed in humans or cattle treated with a single dose of
IVM [59,69]. However, while some recovery of skin Mf densities was apparent, the 7-day regi-
mens displayed a more prolonged suppressive effect on Mf than might have been expected
with IVM [70], with an 87% reduction in pre-treatment Mf load in the EMO7H group by 12
months. Indeed, by the end of the experiment, there were indications that a permanent sup-
pression of female worm fecundity may have been achieved in most of the emodepside-treated
groups. Accordingly, although the embryogram results did not indicate a significant dose-
dependent effect overall, it was clear that oocytes (a stage unaffected by IVM [4,71]) were elim-
inated in the multi-dose treatment groups.
The efficacy of emodepside against adult worm viability was more complex to interpret. In
common with most laboratories conducting assays of macrofilaricidal activity, we applied a
combination of motility scoring and quantification of MTT reduction to assess adult worm
viability. While some laboratories have introduced image analysis algorithms to analyse motil-
ity [72–74], several other research groups continue to use subjective scoring systems as we
applied here [19,75,76]. Increased automation is important for in vitro drug discovery projects
to maximise throughput and reduce operator fatigue but is less frequently used for ex vivo
analysis of worms from animal studies, as fewer parasites are usually involved at any one time.
Importantly, automated motility assessment has never been evaluated on female Onchocerca
spp. worms, which are very sluggish even in the absence of drug treatment, and in vitro drug
screening with O. ochengi continues to use visual scoring, albeit with a more complex six-point
categorisation than we applied here ex vivo [77]. The fact that subjective motility scoring by
technicians blinded to treatment group indicated clear dose-dependent effects of emodepside
against adult worms supports the reliability of this readout.
While all regimens had a significant negative impact on female worm motility, the effects of
emodepside were very slow, and even in the EMO7H group, one animal harboured a female
worm that still displayed some motility at the end of the experiment. Clearly, emodepside
lacks the unambiguous and relatively rapid macrofilaricidal activity of melarsomine, which has
been shown to kill most worms within three months [78]. Furthermore, several immotile
female worms (including from animals in the EMO7H group) were still metabolically active in
the MTT assay at the end of the experiment. Very slow killing of adult filariae is known to be
highly advantageous, as drugs with comparatively rapid macrofilaricidal activity (killing within
a few months), including melarsomine and flubendazole or their derivatives, are associated
with intrinsic toxicity and can induce severe adverse events post treatment [79–81]. Con-
versely, the indirect mode of action of doxycycline against O. volvulus leads to a 70–80%
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reduction in worm lifespan (from ~10 years to 2–3 years) as well as permanent sterilisation of
the females [82], and this ‘death by attrition’ is well tolerated by the host. Although it seems
likely that the vast majority of female worms were sterilised and irreversibly damaged by the
EMO7H regimen, we cannot rule out the possibility that the observed paralysis would eventu-
ally be overcome, perhaps with resumption of embryogenesis in some individuals. This poten-
tial disconnect between motility and viability (i.e., immotile worms are not necessarily dead) is
not unexpected for a tissue-dwelling nematode, but the distinction is often ignored in evalua-
tion of anthelmintics more generally because paralysed gastrointestinal nematodes are expelled
in the faeces. Moreover, our observations over an 18-month experiment highlight the excep-
tionally chronic nature of the Onchocerca lifecycle and the resilience of the adult worms that
can only be thoroughly assessed in natural hosts over an extended period.
Blood glucose has been identified as a simple biomarker for emodepside exposure in
humans [83]. Hence, it was used successfully in this cattle study as a surrogate measure of emo-
depside exposure. In prior pharmacological analyses, the target of emodepside in mammals
was not clear because both neurological symptoms and endocrine effects were observed in tox-
icological studies [84]. Furthermore, the effects on the nervous system were biphasic (excit-
atory then inhibitory). Proposed targeting of the GABAergic system remained inconclusive
because emodepside showed no activity on GABAA receptors or GABA transporters [26,84].
In addition, a reversible increase in blood glucose was observed in toxicological studies, which
was triggered by a decrease in insulin and increase in glucagon excretion [83]. However,
although catabolic dysfunctions comparable to a diabetic type I situation were reported in a rat
model after prolonged, high-dose emodepside exposure (~4–5 mg/kg, over four weeks orally
in diet, was defined as the no-observed-adverse-effect level [83]), it was not a dose-limiting
effect in a recent first-in-human trial [54]. The minor impacts on blood glucose and insulin
levels in humans were only observed under fasting conditions and were not considered as clin-
ically significant or reported as an adverse event [83].
The actual target of emodepside is now known to be the human SLO-1 channel [39]—cal-
cium-activated potassium channel subunit alpha-1 (KCNMA1). Emodepside’s action on
KCNMA1 at 10–100 nM elicits a biphasic, concentration-dependent effect on the current ampli-
tude, with transient facilitation followed by inhibition. These data align closely with the neuro-
logical findings; however, KCNMA1 is an important modulator of both neuronal activities [85]
and secretion in the pancreatic ducts [86], explaining the link with glucose metabolism. There-
fore, it is more likely that the modulatory effect on KCNMA1 is responsible for the side-effects of
emodepside than direct effects on the GABAA receptor. Note that in our assay whereOnchocerca
spp. SLO-1 channels were expressed in Xenopus oocytes, the minimum emodepside concentra-
tion required to induce a detectable increase in current (3 μM) was much higher than the con-
centrations that affect worm motility in vitro [30]. There are several potential reasons for this,
including differences in drug solubility (only 0.1% DMSO was used in the Xenopus oocyte assay
to prevent toxicity) and highly dissimilar assay timescales (milliseconds to minutes with oocytes;
hours to weeks with worm assays). Certainly, there will also be marked differences in SLO-1
expression levels between these systems and the nature of the readouts was entirely distinct.
Several antifilarial drugs, including IVM, diethylcarbamazine and tetracycline antibiotics,
have limited activity in vitro, requiring interactions with the immune system for optimal effi-
cacy [87–90]; although a recent study demonstrated that diethylcarbamazine has direct effects
on B.malayi by inducing temporary paralysis via transient receptor potential channels [74]. In
the case of antibiotics, killing of adult O. ochengi by oxytetracycline (but not melarsomine) is
correlated with eosinophil degranulation on the worm cuticle following depletion ofWolba-
chia [57,60]. However, emodepside in the nanomolar range has been shown to have macrofi-
laricidal activity in vitro against Onchocerca spp. [68] and we observed no clear relationship
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between emodepside dose and PMN infiltration into the nodule. Further studies are required
to determine whether emodepside has any immunomodulatory activity and the extent to
which the immune response may facilitate killing of Mf by this compound.
In conclusion, emodepside has embryotoxic and direct microfilaricidal activity against O.
ochengi in vivo, with prolonged and possibly irreversible effects on adult female fecundity. The
EMO7H regimen exhibited slow-acting and incomplete macrofilaricidal activity within the
18-month timeframe of this field trial, although the observed paralysis of the adult females
may also be irreversible. Emodepside is now set to be evaluated in a phase II trial in Ghana in a
range of regimens, including a single of dose of 30 mg, and daily or twice-daily doses of 15 mg
for either 14 or 10 days, respectively [91]. Thus, our data clearly support emodepside’s current
status as a priority macrofilaricidal candidate with the potential to accelerate the elimination of
onchocerciasis without compromising patient safety.
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Eileen Devaney (University of Glasgow, UK), and colleagues from the Drugs for Neglected
Diseases initiative and Bayer for helpful discussions. We are grateful to the herdsmen and tech-
nical staff of the Veterinary Laboratory of IRAD at Wakwa, Cameroon, and to Catherine Hart-
ley (University of Liverpool) for invaluable support during the main study. Special thanks to
Sabine Obertegger (Bayer, Germany) for data processing and evaluation. Editorial support was
provided by Highfield Communication Ltd (Oxford, UK).
Author Contributions
Conceptualization: Martin Glenschek-Sieberth, Daniel Kulke, Benjamin L. Makepeace.
Data curation: Germanus S. Bah, Sebastian Schneckener, Gabriele M. Schmuck, Carsten Ter-
jung, John Graham-Brown, Martin Glenschek-Sieberth, Benjamin L. Makepeace.
Formal analysis: Sebastian Schneckener, Steffen R. Hahnel, Lucien Rufener, John Graham-
Brown, Benjamin L. Makepeace.
Funding acquisition: Martin Glenschek-Sieberth, Daniel Kulke, Benjamin L. Makepeace.
Investigation: Germanus S. Bah, Steffen R. Hahnel, Nicolas H. Bayang, Helena Fieseler, Ralph
Krebber, Anouk Sarr, Henrietta F. Ngangyung, David D. Ekale, Youssouf M. Mfopit, John
Graham-Brown.
Methodology: Germanus S. Bah, Sebastian Schneckener, Steffen R. Hahnel, Helena Fieseler,
John Graham-Brown, Daniel Kulke.
Project administration: Nicolas H. Bayang, Helena Fieseler, Lucien Rufener, Vincent N.
Tanya, Martin Glenschek-Sieberth, Daniel Kulke, Benjamin L. Makepeace.
Resources: Daniel Kulke.
Supervision: Germanus S. Bah, Vincent N. Tanya, Martin Glenschek-Sieberth, Daniel Kulke,
Benjamin L. Makepeace.
Validation: Sebastian Schneckener, Martin Glenschek-Sieberth, Daniel Kulke, Benjamin L.
Makepeace.
Visualization: Sebastian Schneckener, Steffen R. Hahnel, Helena Fieseler, Martin Glenschek-
Sieberth.
Writing – original draft: Sebastian Schneckener, Steffen R. Hahnel, Helena Fieseler, John
Graham-Brown, Martin Glenschek-Sieberth, Daniel Kulke, Benjamin L. Makepeace.
Writing – review & editing: Germanus S. Bah, Sebastian Schneckener, Steffen R. Hahnel,
Nicolas H. Bayang, Helena Fieseler, Gabriele M. Schmuck, Ralph Krebber, Anouk Sarr,
Carsten Terjung, Henrietta F. Ngangyung, David D. Ekale, Youssouf M. Mfopit, Lucien
PLOS PATHOGENS Efficacy of emodepside in a bovine model of onchocerciasis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009601 June 2, 2021 25 / 30
Rufener, John Graham-Brown, Vincent N. Tanya, Martin Glenschek-Sieberth, Daniel
Kulke, Benjamin L. Makepeace.
References
1. Crump A, Morel CM, Omura S. The onchocerciasis chronicle: from the beginning to the end? Trends in
Parasitology. 2012; 28(7):280–8. https://doi.org/10.1016/j.pt.2012.04.005 PMID: 22633470
2. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence,
prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analy-
sis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545–602. https://doi.org/
10.1016/S0140-6736(16)31678-6 PMID: 27733282
3. Cupp EW, Sauerbrey M, Richards F. Elimination of human onchocerciasis: History of progress and cur-
rent feasibility using ivermectin (Mectizan (R)) monotherapy. Acta Trop. 2011; 120:S100–S8. https://
doi.org/10.1016/j.actatropica.2010.08.009 PMID: 20801094
4. Schulzkey H. Observations on the reproductive-biology of Onchocerca volvulus. Vanderkaay HJ, Over-
bosch D, editors. Leiden: Inst Tropical Medicine Rotterdam—Leiden; 1990. 27–44 p.
5. Richards FO, Eigege A, Umaru J, Kahansim B, Adelamo S, Kadimbo J, et al. The interruption of trans-
mission of human onchocerciasis by an annual mass drug administration program in Plateau and
Nasarawa States, Nigeria. Am J Trop Med Hyg. 2020; 102(3):582–92. Epub 2020/02/12. https://doi.org/
10.4269/ajtmh.19-0577 PMID: 32043442.
6. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocercia-
sis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Sen-
egal. PLoS Negl Trop Dis. 2012; 6(9):e1825. Epub 2012/10/03. https://doi.org/10.1371/journal.pntd.
0001825 PMID: 23029586.
7. Plaisier AP, van Oortmarssen GJ, Remme J, Habbema JD. The reproductive lifespan of Onchocerca
volvulus in West African savanna. Acta Trop. 1991; 48(4):271–84. Epub 1991/02/01. https://doi.org/10.
1016/0001-706x(91)90015-c PMID: 1674401.
8. Kim YE, Remme JH, Steinmann P, Stolk WA, Roungou JB, Tediosi F. Control, elimination, and eradica-
tion of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl Trop
Dis. 2015; 9(4):e0003664. Epub 2015/04/11. https://doi.org/10.1371/journal.pntd.0003664 PMID:
25860569.
9. History of the program: Mectizan Donation Program; 2020 [cited 20/07/2020]. https://mectizan.org/
what/history/.
10. Doyle SR, Bourguinat C, Nana-Djeunga HC, Kengne-Ouafo JA, Pion SDS, Bopda J, et al. Genome-
wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selec-
tive sweeps contribute to loss of drug sensitivity. PLoS Negl Trop Dis. 2017; 11(7):e0005816. Epub
2017/07/27. https://doi.org/10.1371/journal.pntd.0005816 PMID: 28746337.
11. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of
Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-
phase epidemiological study. Lancet. 2007; 369(9578):2021–9. Epub 2007/06/19. https://doi.org/10.
1016/S0140-6736(07)60942-8 PMID: 17574093.
12. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions
after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet.
1997; 350(9070):18–22. Epub 1997/07/05. https://doi.org/10.1016/S0140-6736(96)11094-1 PMID:
9217715.
13. Vinkeles Melchers NVS, Coffeng LE, Boussinesq M, Pedrique B, Pion SDS, Tekle AH, et al. Projected
Number of People With Onchocerciasis-Loiasis Coinfection in Africa, 1995 to 2025. Clin Infect Dis.
2020; 70(11):2281–9. Epub 2019/07/16. https://doi.org/10.1093/cid/ciz647 PMID: 31304961.
14. Geary TG, Mackenzie CD. Progress and challenges in the discovery of macrofilaricidal drugs. Expert
Rev Anti Infect Ther. 2011; 9(8):681–95. Epub 2011/08/09. https://doi.org/10.1586/eri.11.76 PMID:
21819332.
15. Makepeace BL, Tanya VN. 25 Years of the Onchocerca ochengi Model. Trends Parasitol. 2016; 32
(12):966–78. Epub 2016/09/26. https://doi.org/10.1016/j.pt.2016.08.013 PMID: 27665524.
16. Schares G, Hofmann B, Zahner H. Antifilarial activity of macrocyclic lactones: comparative studies with
ivermectin, doramectin, milbemycin A4 oxime, and moxidectin in Litomosoides carinii, Acanthocheilo-
nema viteae, Brugia malayi, and B. pahangi infection of Mastomys coucha. Trop Med Parasitol. 1994;
45(2):97–106. Epub 1994/06/01. PMID: 7939168.
17. Langworthy NG, Renz A, Mackenstedt U, Henkle-Duhrsen K, de Bronsvoort MB, Tanya VN, et al.
Macrofilaricidal activity of tetracycline against the filarial nematode Onchocerca ochengi: elimination of
PLOS PATHOGENS Efficacy of emodepside in a bovine model of onchocerciasis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009601 June 2, 2021 26 / 30
Wolbachia precedes worm death and suggests a dependent relationship. Proc Biol Sci. 2000; 267
(1448):1063–9. Epub 2000/07/08. https://doi.org/10.1098/rspb.2000.1110 PMID: 10885510.
18. Opoku NO, Bakajika DK, Kanza EM, Howard H, Mambandu GL, Nyathirombo A, et al. Single dose mox-
idectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic
Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018; 392
(10154):1207–16. Epub 2018/01/24. https://doi.org/10.1016/S0140-6736(17)32844-1 PMID:
29361335.
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